Prevalence of Secondary Hyperparathyroidism in Hemo- Dialysis Patients
DOI:
https://doi.org/10.47489/szmc.v38i1.420Keywords:
Chronic kidney disease, hemo-dialysis, parathyroid hormone, Secondary hyperparathyroidismAbstract
Introduction: One persistent complication of chronic kidney disease is secondary hyperparathyroidism. Early diagnosis of this disease will reduce morbidity in patients undergoing hemodialysis.
Aims & Objectives: To determine the prevalence of secondary hyperparathyroidism in chronic kidney disease patients at National Institute of Kidney Diseases, SZH Lahore.
Place and Duration of Study: A cross sectional study was conducted at Nephrology Department of Shaikh Zayed Hospital (SZH) Lahore after getting approval from Institutional Review Board of National Health Research Complex (NHRC). It was conducted from September 2023 to November 2023 &140 hemo-dialysis patients were selected.
Material & Methods: We measured serum parathyroid hormone, hemoglobin and other variables, at Biochemistry laboratory of Sheikh Zayed Hospital, in 140 hemodialysis patients. Serum samples were measured for PTH levels using ELISA method. The data was analyzed using SPSS version 20.P value ? 0.05 was considered significant.
Results: Fifteen patients had secondary hyperparathyroidism out of 140 hemodialysis patients. Hyperparathyroidism was observed in 10.71 % of the patients. Hyperparathyroidism patients had significantly low calcium, hemoglobin levels & higher phosphate levels.
Conclusion: The prevalence of secondary hyperparathyroidism is low at 10.71% of patients undergoing hemodialysis at National Institute of Kidney Disease, SZH Lahore.
References
Rodríguez-Ortiz ME, Rodríguez M. Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease. F1000Research.2020;9.https://doi.org/10.12688/f10 00research.22636.1
Hyder R, Sprague SM. Secondary Hyperparathyroidism in a Patient with CKD. Clin J Am Soc Nephrol. 2020;15(7):1041-3. https://doi.org/10.2215/CJN.13411119
van der Plas WY, Noltes ME, van Ginhoven TM, Kruijff S. Secondary and Tertiary Hyperparathyroidism: A Narrative Review. Scand J Surg.2020;109(4):2718.https://doi.org/10.1177/1457 496919866015.
Komaba H, Zhao J, Yamamoto S, Nomura T, Fuller DS, McCullough KP, et al. Secondary hyperparathyroidism, weight loss, and longer term mortality in haemodialysis patients: results from the DOPPS. J Cachexia Sarcopenia Muscle. 2021;12(4):85565.https://doi.org/10.1002/jcsm.1272 2.
Habas E, Sr., Eledrisi M, Khan F, Elzouki AY. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus.2021;13(7):e16388.https://doi.org/10.7759/c ureus.16388
Brandenburg V, Ketteler M. Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future. Nutrients. 2022;14(15):3009.https://doi.org/10.3390/nu141530 09
Bargagli M, Arena M, Naticchia A, Gambaro G, Mazzaferro S, Fuster D, et al. The Role of Diet in Bone and Mineral Metabolism and Secondary Hyperparathyroidism.Nutrients2021;13(7):2328.http s://doi.org/10.3390/nu13072328
Gimba ZM, Abene EE, Agbaji OO, Agaba EI. Secondary hyperparathyroidism among Nigerians with chronic kidney disease. African health sciences.2018;18(2):44657.https://doi.org/10.4314/a hs.v18i2.30
Arbor Research Collaborative for Health, Dialysis Outcomes Practice Patterns Study (DOPPS) Practice Monitor, Available from: https://www.dopps.org/DPMHD/DPMSlideBrowser.aspx Accessed January 2019.
Assumpção LR, de Paula Ramos I, Nunes da Cunha G, de Mello Vianna CM, Araújo Maya MC, Araújo DV. Refractory secondary hyperparathyroidism in waiting list for parathyroidectomy: who we should operate first in a quaternary hospital in Brazil regarding survival. Renal Failure. 2019;41(1):183- 9.https://doi.org/10.1080/0886022X.2019.1590210
Sonkar SK, Singh HP, Sonkar GK, Pandey S. Association of Vitamin D and secondary hyperparathyroidism with anemia in diabetic kidney disease. J Family Med Prim Care. 2018;7(4):815- 8.https://doi.org/10.4103/jfmpc.jfmpc_174_17.
Zhang LX, Zhang B, Liu XY, Wang ZM, Qi P, Zhang TY, et al. Advances in the treatment of secondary and tertiary hyperparathyroidism. Front Endocrinol(Lausanne).2022;13:1059828.https://doi. org/ 10.3389/fendo.2022.1059828.
Reichel H, Seibert E, Tillmann FP, Barck I, Grava A, Schneider KM, et al. Economic burden of secondary hyperparathyroidism in Germany: a matched comparison. Int Urol Nephrol. 2023;55(5):1291300.https://doi.org/10.1007/s11255-022-03425-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Proceedings
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a 